Autoantibodies are increasingly being recognised as a key biomarker class that aids in understanding the interactions between cancer and the immune system.
Viewing cancer through the lens of the immune system has led to the most promising advancements in cancer treatment in recent history. Immuno-oncology therapeutics, such as checkpoint inhibitors (CPIs) are not without their challenges; stimulating the immune system to fight cancer can also cause the immune system to generate self-targeted antibodies (autoantibodies) that cause immune-related adverse events (irAEs).
Autoantibodies are markers of the immune system’s activity and predictive of response to immunotherapy. In fact, we have found that it is often the patients who develop immune-related adverse events, are also the patients that are more likely to respond to the immuno-oncology therapy.
Studying the immune system enables prediction of response to treatment and unwanted immune-related adverse events.
ImmunoINSIGHTS supports drug development programmes throughout their lifecycle to generate safe, effective, and widely adopted therapies.
Oncimmune’s autoantibody profiling platform and expertise in immuno-oncology can:
- Predict response to therapy
- Predict immune-related adverse events (irAEs)
- Detect treatment-specific immune excitation (“heating cold tumours”)
- Indicate activation of both the B and T cell sides of the adaptive immune system
- Predict off-target and non-specific binding effects
- Identify novel target molecules
Autoantibodies are detectable in low volumes of blood collected by standard phlebotomy protocols.